Trial Profile

An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2023 Results of exploratory analysis (n=15) assessing the clonal response patterns in patients with relapsed/refractory acute myeloid leukemia treated with selinexor in a phase II (SAIL) trial, published in the Annals of Hematology.
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
16 May 2019 According to a Karyopharm Therapeutics Media Release, data from this trial will be presented at the upcoming European Hematology Association 2019 Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com